Network pharmacology is a newer tool for discovering drug targets and identifying newer lead molecules to treat diseases with complex pathology.1 Idiopathic pulmonary fibrosis (IPF) is one such disease where currently there is no remedy and only two specific drugs available for the treatment, nintedanib, and pirfenidone.2 Nintedanib is a specific antifibrotic agent that inhibits transforming growth factor beta (TGF-β) and thereby prevents the progression of IPF. The gene discussed is TGFB1; the disease is pulmonary fibrosis.